AbbVie will be among the stocks closing out a busy earnings week. Earnings season tends to draw a lot of interest from investors, but it’s not always the best indicator of a stock’s overall trajectory.
Pfizer has bought privately held Amplyx Pharmaceuticals for an undisclosed sum, gaining experimental antifungal and antiviral treatments as the world’s attention turns more toward infectious diseases.
Surgical Theater’s technology builds 3D models of an individual patient’s anatomy from CT and MRI scans to offer surgeons an immersive, 360-degree fly-through view.
The self-styled gene therapy “development engine” raised $120 million to quickly expand capacity for its adeno-associated virus (AAV) contract manufacturing services—and triple its workforce along the way.
Bristol Myers Squibb (BMS) is planning to invest in a new cell therapy manufacturing site based in Leiden in the Netherlands.
